Chiesi Farmaceutici S.p.a.

This study tests a gel called Oleogel-S10 on skin wounds from two types of epidermolysis bullosa (EB), a rare genetic condition that makes skin very fragile. About 6 Japanese children and adults will apply the gel to their wounds at dressing changes for 45 days, with the option t…

This study compares a new version of an asthma inhaler that uses a more environmentally friendly propellant to the current inhaler. Researchers want to make sure both versions work equally well for people with mild to moderate asthma. About 780 adults will participate in this pha…

This study is testing an experimental drug called PRX-102 in children and teens aged 2 to 18 with Fabry disease, a rare genetic condition. The goal is to see if the drug is safe and helps control the disease by replacing a missing enzyme. About 22 participants will receive the dr…

This study follows about 100 adults with Fabry disease who are taking or planning to take the medication Elfabrio. Researchers will track kidney function, heart health, and disease markers over time to see how safe and effective the drug is in everyday care. The goal is to better…

This study tests a new enzyme replacement therapy called pegunigalsidase alfa in Japanese patients with Fabry disease, a rare genetic disorder. About 16 people aged 13 to 70 will receive the treatment to see if it is safe and helps control the disease. The goal is to manage sympt…

This study tests the safety of an inhaled drug called CHF6333 in healthy volunteers and people with bronchiectasis, a chronic lung condition. In the first part, participants receive a single dose; in the second part, people with bronchiectasis receive repeated doses. The goal is …

This study is a worldwide registry that will follow about 10 women with Fabry disease who take the medication pegunigalsidase alfa during pregnancy or while breastfeeding. Researchers will track the health of both mothers and their babies for up to one year after birth. The goal …

This early-stage study is testing a new drug called CHF6467, given as a nasal spray, in 68 healthy adults. The main goal is to see if it is safe and how the body handles it, including measuring drug levels in blood and spinal fluid. Participants will receive either single or mult…